JPMorgan Chase & Co. Lowers BioNTech (NASDAQ:BNTX) Price Target to $122.00

BioNTech (NASDAQ:BNTX) had its price target reduced by analysts at JPMorgan Chase & Co. from $124.00 to $122.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 1.06% from the company’s previous close.

BNTX has been the subject of a number of other reports. Bank of America lifted their price target on shares of BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, September 16th. Jefferies Financial Group raised shares of BioNTech from a “hold” rating to a “buy” rating and raised their price objective for the stock from $96.00 to $150.00 in a research report on Tuesday, September 17th. The Goldman Sachs Group raised BioNTech from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $90.00 to $137.00 in a research report on Friday, November 8th. Berenberg Bank began coverage on shares of BioNTech in a research note on Tuesday, November 19th. They issued a “buy” rating and a $130.00 price objective on the stock. Finally, Hsbc Global Res raised shares of BioNTech from a “hold” rating to a “strong-buy” rating in a report on Friday, August 2nd. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $138.67.

BioNTech Trading Up 1.8 %

NASDAQ BNTX opened at $120.72 on Tuesday. BioNTech has a 52 week low of $76.53 and a 52 week high of $131.49. The company has a 50 day moving average price of $113.42 and a 200 day moving average price of $98.19. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The firm has a market cap of $28.94 billion, a PE ratio of -57.48 and a beta of 0.26.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. The company had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. BioNTech’s revenue for the quarter was up 38.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.73 earnings per share. As a group, sell-side analysts forecast that BioNTech will post -3.68 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. GAMMA Investing LLC raised its holdings in shares of BioNTech by 21.7% in the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock worth $74,000 after buying an additional 111 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in shares of BioNTech by 106.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after purchasing an additional 252 shares during the period. Blue Trust Inc. increased its stake in BioNTech by 491.1% during the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after purchasing an additional 388 shares in the last quarter. Gallacher Capital Management LLC boosted its position in BioNTech by 12.1% during the 2nd quarter. Gallacher Capital Management LLC now owns 3,657 shares of the company’s stock worth $294,000 after acquiring an additional 395 shares during the last quarter. Finally, TD Asset Management Inc raised its holdings in shares of BioNTech by 6.1% in the second quarter. TD Asset Management Inc now owns 7,590 shares of the company’s stock valued at $612,000 after purchasing an additional 435 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.